In ®Entresto we trust
Abstract Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-11-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40959-020-00083-7 |